Who we are
What we do
Investor Centre
Media Relations
Contact

phone
+61 (0)3 9208 4182

Current drugs in the market offer, at most, a few months of extra life or tumor stabilization

We are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors.

Distinct advantages that will differentiate it from other treatments

Our goal is to introduce a cancer drug with a significantly improved therapeutic index compared to already available treatments for rapidly progressing tumours (of which there are few).

Become an Investor & help make a difference in patients' lives

We are actively seeking additional investors to help transform our drug development company into a leading oncology player, focusing on providing quality of life and no serious side effects.

Our Business

The core capability of the Propanc is the intimate knowledge of active biological cancer therapies that can be used for late stage cancer patients.

Research & Development

At Propanc our goal is to introduce a cancer drug with a significantly improved therapeutic index for rapidly progressing tumors.

Investor Relations

We are actively seeking additional investors to help transform our drug development company into a leading oncology player.

Who We Are

Our Thinking

The new cancer drug was based on the original work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago, using fresh pancreatic enzyme extracts.

Through advancements in science and technology, our company has discovered an opportunity to commercialise an improved version of this drug administered once daily in an outpatient setting. Our intention is to supply this treatment to markets worldwide. Propanc was established in 2007 and located in Melbourne, Australia.

Share Propanc & help to save lives

Our intention is to supply this treatment to markets worldwide & improve quality of life

Disease Background

We focus on metastatic cancer patients. Metastasis refers to the ability of cancer cells to penetrate into lymphatic and blood vessels, circulate through the bloodstream, and then invade normal tissues elsewhere in the body...
Read More

Company Charter

The chances of developing cancer increase as a person gets older because more time has been available for mutations to accumulate. As people are living longer, they have a longer exposure time to factors linked to cancer...
Read More

Suscribe to our Newsletter

Home
Investor Centre
Media Relations
Contact

Who We Are

Our Business
Company Charter
Key Highlights

Board Of Directors & Managers
Scientific Advisory Board
Our Advantage

What We Do

Research & Development
Our Technology
Current Therapies
Disease Background
Mechanism Of Action

Target Indications
Development Strategy
Milestones
R & D Pipeline